Lexeo Therapeutics Says LX2020 Stabilizes Arrythmia Burden in Phase 1/2 Trial

MT Newswires Live

Jan 12

Lexeo Therapeutics (LXEO) said Monday that arrythmia burden stabilized or improved in most participants of its phase 1/2 trial of LX2020 in patients with PKP2-associated arrhythmogenic cardiomyopathy.

The investigational gene therapy was "generally well tolerated" across 10 dosed participants, with no significant complement activation and manageable liver function tests elevations that resolved without any complication or hospitalization, according to Lexeo.

The company also said treatment led to strong transduction and increased PKP2 protein expression across participants with dose-dependent response.

Lexeo said 12-month data from all high-dose participants is expected in Q4, with regulatory engagement planned within the year.

Shares of Lexeo Therapeutics fell more than 34% in recent trading Monday.

Price: 6.92, Change: -3.62, Percent Change: -34.35

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2602544369"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2602544369\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2602544369?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 23:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602544369","market":"nz","top_or_hot":-1,"title":"Lexeo Therapeutics Says LX2020 Stabilizes Arrythmia Burden in Phase 1/2 Trial","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/LXEO\">Lexeo Therapeutics</a> (LXEO) said Monday that arrythmia burden stabilized or improved in most participants of its phase 1/2 trial of LX2020 in patients with PKP2-associated arrhythmogenic cardiomyopathy.</p><p>The investigational gene therapy was \"generally well tolerated\" across 10 dosed participants, with no significant complement activation and manageable liver function tests elevations that resolved without any complication or hospitalization, according to Lexeo.</p><p>The company also said treatment led to strong transduction and increased PKP2 protein expression across participants with dose-dependent response.</p><p>Lexeo said 12-month data from all high-dose participants is expected in Q4, with regulatory engagement planned within the year.</p><p>Shares of Lexeo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> fell more than 34% in recent trading Monday.</p><p>Price: 6.92, Change: -3.62, Percent Change: -34.35</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lexeo Therapeutics Says LX2020 Stabilizes Arrythmia Burden in Phase 1/2 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLexeo Therapeutics Says LX2020 Stabilizes Arrythmia Burden in Phase 1/2 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-12 23:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/LXEO\">Lexeo Therapeutics</a> (LXEO) said Monday that arrythmia burden stabilized or improved in most participants of its phase 1/2 trial of LX2020 in patients with PKP2-associated arrhythmogenic cardiomyopathy.</p><p>The investigational gene therapy was \"generally well tolerated\" across 10 dosed participants, with no significant complement activation and manageable liver function tests elevations that resolved without any complication or hospitalization, according to Lexeo.</p><p>The company also said treatment led to strong transduction and increased PKP2 protein expression across participants with dose-dependent response.</p><p>Lexeo said 12-month data from all high-dose participants is expected in Q4, with regulatory engagement planned within the year.</p><p>Shares of Lexeo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> fell more than 34% in recent trading Monday.</p><p>Price: 6.92, Change: -3.62, Percent Change: -34.35</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2602544369","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602544369","pubTimestamp":1768233231,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Lexeo Therapeutics  said Monday that arrythmia burden stabilized or improved in most participants of its phase 1/2 trial of LX2020 in patients with PKP2-associated arrhythmogenic cardiomyopathy.The investigational gene therapy was \"generally well tolerated\" across 10 dosed participants, with no significant complement activation and manageable liver function tests elevations that resolved without any complication or hospitalization, according to Lexeo.The company also said treatment led to strong transduction and increased PKP2 protein expression across participants with dose-dependent response.Lexeo said 12-month data from all high-dose participants is expected in Q4, with regulatory engagement planned within the year.Shares of Lexeo Therapeutics fell more than 34% in recent trading Monday.Price: 6.92, Change: -3.62, Percent Change: -34.35","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LXEO":"Lexeo Therapeutics"},"translate_title":"Lexeo Therapeutics称LX2020在1/2期试验中稳定心律失常负担","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LXEO":1.5},"content_text":"Lexeo Therapeutics (LXEO) said Monday that arrythmia burden stabilized or improved in most participants of its phase 1/2 trial of LX2020 in patients with PKP2-associated arrhythmogenic cardiomyopathy.The investigational gene therapy was \"generally well tolerated\" across 10 dosed participants, with no significant complement activation and manageable liver function tests elevations that resolved without any complication or hospitalization, according to Lexeo.The company also said treatment led to strong transduction and increased PKP2 protein expression across participants with dose-dependent response.Lexeo said 12-month data from all high-dose participants is expected in Q4, with regulatory engagement planned within the year.Shares of Lexeo Therapeutics fell more than 34% in recent trading Monday.Price: 6.92, Change: -3.62, Percent Change: -34.35","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}